Page 38 - Breakthrough Device News Today

Founded in 2016, Alpha Tau developed a breakthrough cancer treatment called Alpha DaRT (Dіffusіng Alpha-emіtters Radіatіon Therapy).

/PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq:AEMD), a medical device technology company focused on unmet needs in global health, today announced that it has...

Ibex Medical Analytics, the pioneer in AI-powered cancer diagnostics, today announced the granting of Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA), which will help fast track the clinical review and regulatory approval of its platform.

/PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on unmet needs in global health, today announced the...

/PRNewswire/ -- Varian, a Siemens Healthineers company, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough...

Boston Scientific Initiates First Coronary Drug-Coated Balloon Study in the U.S. AGENT IDE will evaluate the AGENT DCB as potential therapy for patients with in-stent restenosis, may offer alternative to repeated stenting or radiation therapy May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the AGENT Drug-Coated Balloon (DCB), the first clinical trial in the U.S. to evaluate the safety and effectiveness of a DCB in patients with coronary in-ste...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 13, 2021) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN) today announced that it will sponsor a symposium

May 11, 2021 Company Expands Global Reach with Latest Endovascular Aneurysm Repair (EVAR) Technology IRVINE, Calif.—May 11, 2021—Endologix LLC today announced the first implant of its ALTO® Abdominal Stent Graft in Canada following recent approval from Health Canada. ALTO was also recently approved for commercial sale in Argentina. “We are excited to extend the global reach of ALTO, which is now available in Europe, New Zealand, Canada and Argentina, as well as the U.S.,” said Prof. ...

Press release content from NewMediaWire. The AP news staff was not involved in its creation. Neovasc Announces First Patient Enrollment in COSIMA Trial NeovascMay 10, 2021 GMT VANCOUVER and MINNEAPOLIS - (NewMediaWire) - May 10, 2021 - Neovasc  Inc. (“Neovasc” or the “Company”) ( NASDAQ,  TSX: NVCN) today announced that the first patient has been enrolled in the COronarySInus Reducer for the Treatment of Refractory MicrovascularAngina (“COSIMA”) trial. The enrollment occurred at...

Message : Required fields Except for statements of historical fact, certain information described in this Form 10-Q report contains "forward-looking statements" that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will," "would" or similar words. The statements that contain these or similar words should be read carefully because these statements dis...